NO20084698L - Metode for fremstilling av indazolyl-ureaer som inhiberer vanilloidreseptor subtype 1(VR1) - Google Patents

Metode for fremstilling av indazolyl-ureaer som inhiberer vanilloidreseptor subtype 1(VR1)

Info

Publication number
NO20084698L
NO20084698L NO20084698A NO20084698A NO20084698L NO 20084698 L NO20084698 L NO 20084698L NO 20084698 A NO20084698 A NO 20084698A NO 20084698 A NO20084698 A NO 20084698A NO 20084698 L NO20084698 L NO 20084698L
Authority
NO
Norway
Prior art keywords
preparation
receptor subtype
vanilloid receptor
indazolyl
inhibit vanilloid
Prior art date
Application number
NO20084698A
Other languages
English (en)
Norwegian (no)
Inventor
Kirill A Lukin
Margaret Chi-Ping Hsu
Dilinie P Fernando
Brian J Kotecki
Marvin R Leanna
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of NO20084698L publication Critical patent/NO20084698L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
NO20084698A 2006-04-14 2008-11-07 Metode for fremstilling av indazolyl-ureaer som inhiberer vanilloidreseptor subtype 1(VR1) NO20084698L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79209906P 2006-04-14 2006-04-14
PCT/US2007/066605 WO2007121339A2 (en) 2006-04-14 2007-04-13 Process for the preparation of indazolyl ureas that inhibit vanilloid subtype 1 (vr1) receptors

Publications (1)

Publication Number Publication Date
NO20084698L true NO20084698L (no) 2008-11-07

Family

ID=38610399

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084698A NO20084698L (no) 2006-04-14 2008-11-07 Metode for fremstilling av indazolyl-ureaer som inhiberer vanilloidreseptor subtype 1(VR1)

Country Status (20)

Country Link
US (2) US7847104B2 (es)
EP (1) EP2012779B1 (es)
JP (1) JP2009533474A (es)
KR (2) KR101118932B1 (es)
CN (4) CN102321025A (es)
AU (1) AU2007238019B2 (es)
BR (1) BRPI0709963A2 (es)
CA (1) CA2647261A1 (es)
CR (1) CR10357A (es)
EC (1) ECSP088878A (es)
ES (1) ES2385404T3 (es)
MX (1) MX2008013205A (es)
MY (1) MY145334A (es)
NO (1) NO20084698L (es)
NZ (1) NZ571705A (es)
RU (1) RU2446161C2 (es)
TW (1) TW200815362A (es)
UA (1) UA94100C2 (es)
WO (1) WO2007121339A2 (es)
ZA (1) ZA200808596B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8354528B2 (en) * 2007-10-25 2013-01-15 Genentech, Inc. Process for making thienopyrimidine compounds
EP2323989A4 (en) * 2008-03-20 2011-06-22 Abbott Lab METHODS FOR PREPARING AGENTS FOR THE CENTRAL NERVOUS SYSTEM THAT ARE TRPV1 ANTAGONISTS
CN102070420B (zh) * 2011-01-04 2013-12-18 常州大学 一种2-溴-6-氟苯甲醛的制备方法
US20140275505A1 (en) * 2013-03-13 2014-09-18 Dow Agrosciences Llc Process for the preparation of certain triaryl rhamnose carbamates
CN109476646A (zh) 2016-07-12 2019-03-15 拜耳作物科学股份公司 作为害虫防治剂的双环化合物
CN106977535A (zh) * 2017-04-28 2017-07-25 大连联化化学有限公司 一种合成2‑氰基3‑氟苯硼酸工艺

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1054833A (es) * 1963-08-09
DE2458965C3 (de) * 1974-12-13 1979-10-11 Bayer Ag, 5090 Leverkusen 3-Amino-indazol-N-carbonsäure-Derivate, Verfahren zu ihrer Herstellung sowie sie enthaltende Arzneimittel
US5905080A (en) 1993-08-20 1999-05-18 Smithkline Beecham, P.L.C. Amide and urea derivatives as 5HT1D receptor antagonists
JP5039268B2 (ja) * 2001-10-26 2012-10-03 アベンティス・ファーマスーティカルズ・インコーポレイテツド ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用
CA2480497A1 (en) 2002-04-26 2003-11-06 Pharmacia & Upjohn Company Substituted pyrazine derivatives
JP4810427B2 (ja) * 2003-05-22 2011-11-09 アボット・ラボラトリーズ インダゾール、ベンズイソオキサゾールおよびベンズイソチアゾールキナーゼ阻害剤
US7015233B2 (en) * 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
US7375126B2 (en) * 2003-06-12 2008-05-20 Abbott Laboratories Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
AU2004275694B2 (en) * 2003-06-30 2008-03-06 Bizbiotech Co., Ltd. Compounds, compositions and methods
US20050267096A1 (en) * 2004-05-26 2005-12-01 Pfizer Inc New indazole and indolone derivatives and their use pharmaceuticals
WO2006020070A2 (en) * 2004-07-16 2006-02-23 Teva Pharmaceutical Industries, Ltd. Indanylamino uracils and their use as antioxidants and neuroprotectants
US20070021450A1 (en) * 2004-07-16 2007-01-25 Benjamin Sklarz Indanylamino uracils and their use as antioxidants and neuroprotectants
CA2618513A1 (en) * 2005-08-11 2007-02-22 Ariad Pharmaceuticals, Inc. Unsaturated heterocyclic derivatives
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
US20070149508A1 (en) * 2005-11-02 2007-06-28 Targegen, Inc. Six membered heteroaromatic inhibitors targeting resistant kinase mutations
JP2009517430A (ja) * 2005-11-30 2009-04-30 エフ．ホフマン−ラ ロシュ アーゲー ３−アミノ−１−アリールプロピルインドール類及びアザ置換インドール類

Also Published As

Publication number Publication date
US8519186B2 (en) 2013-08-27
CN102140081A (zh) 2011-08-03
CN101466374A (zh) 2009-06-24
US20110040102A1 (en) 2011-02-17
AU2007238019B2 (en) 2013-03-14
UA94100C2 (ru) 2011-04-11
KR101118932B1 (ko) 2012-02-27
RU2446161C2 (ru) 2012-03-27
ES2385404T3 (es) 2012-07-24
ZA200808596B (en) 2010-03-31
WO2007121339A3 (en) 2008-10-02
EP2012779A2 (en) 2009-01-14
HK1123725A1 (en) 2009-06-26
CR10357A (es) 2008-12-11
US20070244178A1 (en) 2007-10-18
WO2007121339A2 (en) 2007-10-25
CN102775350A (zh) 2012-11-14
CN102321025A (zh) 2012-01-18
ECSP088878A (es) 2008-12-30
NZ571705A (en) 2012-03-30
MX2008013205A (es) 2008-10-22
CN101466374B (zh) 2012-03-21
CA2647261A1 (en) 2007-10-25
AU2007238019A1 (en) 2007-10-25
EP2012779A4 (en) 2010-11-24
KR20090003335A (ko) 2009-01-09
TW200815362A (en) 2008-04-01
BRPI0709963A2 (pt) 2011-08-02
EP2012779B1 (en) 2012-05-16
MY145334A (en) 2012-01-31
KR20110017464A (ko) 2011-02-21
US7847104B2 (en) 2010-12-07
RU2008144961A (ru) 2010-05-20
JP2009533474A (ja) 2009-09-17

Similar Documents

Publication Publication Date Title
NO20072435L (no) CGRP-reseptorantagonister
IL187208A0 (en) Antagonists of the vanilloid receptor subtype 1 (vr1) and uses thereof
ATE537170T1 (de) Cgrp-rezeptorantagonisten
ATE463495T1 (de) Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten
DE602005020655D1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
CY1109854T1 (el) Παραγωγα αζαδικυκλο(3.1.0)εξανιου χρησιμα ως ρυθμιστες υποδοχεων d3 ντοπαμινης
MX2009005462A (es) Analogos de 7,8-saturados-4,5-epoxi-morfinano.
ATE429427T1 (de) Pyrimidinderivate als orexin-rezeptorantagonisten
MX2010008713A (es) Derivados de 5,6-bisaril-2-piridina-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de la urotensina ii.
NO20084698L (no) Metode for fremstilling av indazolyl-ureaer som inhiberer vanilloidreseptor subtype 1(VR1)
DE602005027230D1 (de) Cgrp-rezeptorantagonisten
ATE552246T1 (de) Substituierte aryloxy-n- bicyclomethylacetamidverbindungen als vr1- antagonisten
EA200700365A1 (ru) Производные индол-2-карбоксамидина как антагонисты nmda рецептора
ATE512142T1 (de) Pyrimidin- und chinazolinderivate als modulatoren der somatostatin-rezeptor aktivität
WO2006041830A3 (en) Cgrp receptor antagonists
AR064306A1 (es) Antagonistas del receptor de angiotensina ii
EP1617806A4 (en) SELECTIVE SPIROCYCLIC GLUCOCORTICOID RECEPTOR MODULATORS
TW200714587A (en) Biphenyl compounds useful as muscarinic receptor antagonists
MY149973A (en) 3-carboxypropyl-aminotetralin derivatives as mu opioid receptor antagonists
DE602005027870D1 (de) Cgrp-rezeptorantagonisten
MX2007004661A (es) Derivados de 1-(hetero)aril-3-amino-pirrolidina para usarse como antagonistas del receptor mglur3.
DE602006014097D1 (de) Cgrp-rezeptorantagonisten
ATE546448T1 (de) Urotensin-ii-rezeptorantagonisten
ATE461172T1 (de) Azetidinderivate als antagonisten des muskarinrezeptors
EA200801549A1 (ru) Новые производные фенантридина в качестве антагонистов брадикинина

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ABBVIE INC., US

FC2A Withdrawal, rejection or dismissal of laid open patent application